These statements represent the summation of expert opinion and should be interpreted in the context of the individual patient and the managing healthcare provider who knows her or him. These are not guidelines, and these may be updated as knowledge and the situation evolve. To date, there are limited data about patients with IBD who have COVID-19.
A patient with moderately to severely active Crohn’s disease or ulcerative colitis should be treated with the same therapies they would choose in the pre-COVID-19 era
Drug Class | Drugs | Increases the risk of COVID-19 | Reduce the dose or discontinue drug to avoid COVID-19 | Stop treatment if you develop or test positive for COVID-19 | |
---|---|---|---|---|---|
5-ASA Mesalamine | Apriso, Asacol HD, Canasa, Delzicol, Lialda | No | No | No | |
Budesonide | Entocort, Uceris | No | No | ? | |
Prednisone | Yes | Yes | Yes | ||
Azathioprine | Imuran 6MP | ? | No | Yes | |
Methotrexate | ? | No | Yes | ||
Anti-TNF | Remicade (infliximab), Cimzia (certolizumab), Humira (adalimumab), Simponi (golimumab) | ? | No | Yes | |
Anti-integrin | Entyvio (vedolizumab) | No | No | ? | |
Interlukin inhibitor | Stelara (ustekinumab) | No | No | ? | |
Jak Inhibitor | Xeljanz (tofacitinib) | ? | No | Yes | |
Combination therapy | Azathioprine or Methotrexate with Anti-TNF | ? | ? | Yes |
*? indicates “uncertain at this time”
To access the full IOIBD Update on COVID-19 for Patients with Crohn’s Disease and Ulcerative Colitis, visit: https://www.ioibd.org/ioibd-update-on-covid19-for-patients-with-crohns-disease-and-ulcerative-colitis/
Additional information can be found here:
As always, if you have specific questions related to your individual condition or treatment, we recommend you consult with your gastroenterologist.